Why the study?
Does a paclitaxel-coated balloon strategy reduce 9-month late lumen loss non-inferiorly to new-generation drug-eluting stents in patients with coronary de novo lesions?
Does a paclitaxel-coated balloon strategy reduce 9-month late lumen loss non-inferiorly to new-generation drug-eluting stents in patients with coronary de novo lesions?
A paclitaxel-coated balloon-only strategy is non-inferior to new-generation drug-eluting stents regarding angiographic late lumen loss at 9 months for coronary de novo lesions.
Non-inferior late lumen loss supports DCB-only use in de novo lesions; extends DCB evidence from restenosis to native vessels.
In this prospective study, the DCB only strategy for de novo lesion was non-inferior to the new-generation DES in terms of 9-month late lumen loss.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: